Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 in Treatment-Seeking Individuals With Methamphetamine Use Disorder

NCT05034874 is registered in ClinicalTrials.gov with InterveXion Therapeutics, LLC as lead sponsor.

NCT NCT05034874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05034874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200 in Treatment-Seeking Individuals With Methamphetamine Use Disorder
Lead sponsor
InterveXion Therapeutics, LLC
Phase
Phase 2
Overall status
Terminated
Start date
June 9, 2022
Completion date
November 7, 2023
Enrollment
61 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

methamphetamine abuse, methamphetamine-dependence